FDA Approvals
FDA Approves Roche’s Wilserdly for ESR1-Mutated Advanced Breast Cancer
The oral drug, given with everolimus, cut the risk of progression or death by 62% in a phase III trial; a second decision is due Nov. 30.
The newest stories in The Monochrome Chronicles that mention Cancer, newest first.
FDA Approvals
The oral drug, given with everolimus, cut the risk of progression or death by 62% in a phase III trial; a second decision is due Nov. 30.
FDA
The agency said ivonescimab’s delay in disease progression was not enough without a statistically significant gain in overall survival; Summit says it will keep developing the drug.
Study
Women with the highest blood levels of PFOS and PFOA had more ER-negative tumors. No link appeared for breast cancer overall.
Cancer Screening
The first major update since 2010 replaces shared decision-making with a direct recommendation; the federal task force has not changed its advice, STAT reported.
FDA
Daraxonrasib, sold as Rasonque, roughly doubled median survival against chemotherapy in a 500-patient open-label trial, the agency said.
Cancer
A phase 3 trial of an oral RAS-targeting drug reported a median survival of 13.2 months against about 6.7 months on chemotherapy in patients whose disease had already been treated once.
Cancer
A JAMA research letter from American Cancer Society scientists finds colorectal cancer moved from fifth to first among cancer deaths in Americans younger than 50, even as deaths from other major cancers fell.